positive; 45.7% (N=21) were RF-ELISA positive and RF-nephelometry negative and 4.3% (N=2) the opposite, without a statistical significance. Conclusions: ELISA is superior to nephelometry detecting RF in patients with RA, as also in quantifying high-positive values. Background: Detection of auto-antibodies directed against nuclear antigens (antinuclear antibodies or ANA) have important diagnostic and prognostic implications in connective tissue diseases (CTD). The conventional indirect immunofluorescence assay on HEp-2 cell line (ANA-IIF) is the most commonly used method to detect ANA. The ANA-IIF can be labor intensive and suffers from lack of specificity. Objectives: To evaluate the utility of a new fluoroenzyme Immunoassay "EliA-CTD" as an alternative for screening patients suspected for autoimmune connective tissue diseases. Methods: Sixteen Hundread (1600) consecutive patients' sera submitted for anti-nuclear antibodies were tested using the ANA-IIF (Diasorin S.P.A, Saluggia, Italy) and the new EliA-CTD screen (Phadia GmbH, Frieiburg, Germany). ANA testing was ordered by both primary and secondary care physicians. The EliA-CTD screening assay is a fluoroenzyme immunoassay which is performed on the Phadia-250 automated platform. The EliA-CTD assay contains ANA-targeted recombinant antigens including dsDNA, Sm-D, Rib-P, PCNA, U1-RNP (70, A, C), SS-A/Ro, SS-B/La, Centromere B, Scl-70, Fibrillarin, RNA Polymerase III, Jo-1, Mi-2, and PM-scl. The test results are expressed as ratio, with >1.0 considered positive. For ANA-IIF, the cut off for positive results was 1:40 or greater. Additionally, further testing for dsDNA and other extractable nuclear antigens (ENA) was undertaken on a subset of sera that were ANA-IIF+ or whenever there was discrepancy between the two methods.
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Conclusions:
The new automated EliA-CTD assay shows superior sensitivity and specificity compared to the conventional labor intensive ANA-IIF. The EliA-CTD can be used as an upfront screening tool for connective tissue diseases. Depending on the clinical details, any EliA-CTD positive results could be reflexly followed by additional testing including ANA-IIF testing to elucidate the titer and pattern. 
